Comparative profile for COVID-19 cases from China and North America: Clinical symptoms, comorbidities and disease biomarkers

Table 3 Meta-analyses for the prevalence of comorbidities in the study populations of coronavirus disease 2019 cases from China and North America

Comorbidities	China						North America						P2 value
	Number of cases (n)1	Meta-analysis		Heterogenicity			Number of cases (n)	Meta-analysis		Heterogenicity
		Frequency (%)	95%CI	τ2	Q	I2		Frequency (%)	95%CI	τ2	Q	I2
Obesity	666	2.1	0.1-4.3	0.001	54	91	26895	22.9	18.1-27.9	0.016	2130	99	< 0.001
Hypertension	22650	25.6	23.8-27.4	0.013	2154	91	34442	47.6	41.0-54.2	0.034	5347	99	< 0.001
Diabetes	23770	11.8	10.9-12.6	0.002	980	79	35384	34.1	30.1-38.2	0.015	3169	98	< 0.001
Cardiovascular diseases	22439	7.9	7.1-8.7	0.002	1339	86	33459	20.8	18.4-23.3	0.005	4379	99	< 0.001
COPD	17263	3.3	2.8-3.7	0.001	540	78	29697	11.6	10.1-13.1	0.001	716	94	< 0.001
Cancer	16527	9.7	7.1-12.2	0.017	19185	99	24564	6.6	5.5-7.6	0.001	254	89	< 0.001
Liver diseases (any)	11087	3.3	2.8-3.9	0.001	276	68	9706	3.1	2.1-4.2	0.001	98	83	0.414
Chronic kidney diseases	16394	2.1	1.7-2.4	0.001	236	59	30761	11.8	10.0-13.6	0.002	1082	86	< 0.001

¹n is the number of subjects assessed for each comorbidity as per the source database[7].

²Chi Square test for the difference between prevalence of comorbidity in China and North America. COPD: Chronic obstructive pulmonary disease.